Roche Can Launch Mircera 10 Months Before Amgen's EPO Patent Expires
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen inked a license agreement with Roche in settling its patent infringement suit.
You may also be interested in...
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Teva Can Launch Neupogen Biosimilar One Month Before Patent Expiration
Under a settlement with Amgen, Teva can begin selling its G-CSF product in November 2013; the launch may be sooner if a third party launches or wins an infringement suit.
Teva Can Launch Neupogen Biosimilar One Month Before Patent Expiration
Under a settlement with Amgen, Teva can begin selling its G-CSF product in November 2013; the launch may be sooner if a third party launches or wins an infringement suit.